Our Team
ERIC DUCKERS, MD PHD FESC FACC
VasoRx CEO, and Director
Dr.Duckers is an academic and biopharmaceutical veteran with 35 years of experience in the Academia and Biotechnology industry and has been involved in numerous successful startup ventures. Dr. Duckers received his B.S. in Pharmacy and Medical Management from the University of Utrecht and the University of Rotterdam, and completed his Medical Training with honors at the University of Utrecht. During his medical training, he obtained his PhD in Biochemistry and Molecular Biology with honors from the Rudolf Magnus Institute for Neuroscience at the University of Utrecht, as one of the youngest recipients. He continued his medical training at the New England Medical Center, Massachusetts Medical Center and Utrecht University Medical Center. Subsequently, he conducted a postdoctoral fellowship in gene therapy in the CNS at Netherlands Institute for NeuroScience and later, in the laboratories of Elizabeth and Gary J Nabel. At the CardioVascular Research Center and Howard Hughes Medical Institute at the University of Michigan, Ann Arbor, to study cardiovascular gene therapy and the molecular regulation of vascular proliferative disease.
At the Erasmus University of Rotterdam, he gained further training in molecular and cell biology, while being trained as Cardiologist and interventional Cardiologist, under supervision of profs. Frank Grosfeld, Jos Roelandt, Maarten Simoons and Patrick Serruys. During his training, he also built up his research group in Molecular and Cellular Cardiology at the University of Rotterdam. His research focused on the genetic regulation of ischemic heart disease and neoangiogenesis, biomarker discovery, as well as development and assessment of stem cell therapy heart disease. He designed and led numerous national and international clinical trials (including in the field of imaging and intervention in interventional cardiology, and vascular gene and cell therapy), and led international scientific consortia in new biotechnology in cardiovascular medicine and interventional cardiology. In 2012, he was offered a chair in Molecular and Cellular Biology of Cardiovascular System, as well as Invasive Cardiology, at the University of Rotterdam. From 2013-2016, he was the Chief Medical Officer and/or Chief Executive Officer of start-up companies including BioTxs, CardioGenx, Okyanos, and BioCardia, where he set up and managed the Clinical division and initiated various pivotal clinical programs at US, EU and Canadian sites (2016-2020). Dr. Duckers also headed the Clinical and Regulatory dept of Beren Therapeutics Corporation, where he initiated their clinical programs. In 2022, he accepted the position of CEO of VasoRx.
Dr. Duckers received a B.S. in Pharmacy and Medicine from the University of Utrecht, as a well as a B.S. in Management of Medical Health Care from the University of Rotterdam, a MS/ MD degree in Medicine from the University Utrecht, and a PhD in Neuropharmacology and Molecular Biology from the University of Utrecht (with a focus on CNS regeneration). His work so far has resulted in >250 biotechnology publications and numerous composition, process, and method patents.
REBECQUE LABA
VP of Finance and Administration.
Ms. Laba serves as our Vice President Finance and Administration since November 2020. She has over 25 years of experience in biotechnology serving in executive roles with direct oversight of finance and accounting, business operations, and corporate governance, among others. Ms. Laba was Vice President Finance and Corporate Operations at Celladon Corporation where she led the company through an IPO. Prior to Celladon she held senior roles at Idun Pharmaceuticals having a lead role in its acquisition by Pfizer. Ms. Laba has raised over $350MM in private and public equity, and debt financings and has participated in multiple M&A transactions.
George Reed
CMC Lead
Prof.Robert Langer
Chair of Scientific Advisory Board, Founder of VasoRx
Robert S. Langer is one of 11 Institute Professors at MIT. Dr. Langer has written more than 1,570 articles. He also has over 1,400 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history (h-index 304 with over 374,000 citations according to Google Scholar). He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999-2002.
Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators worldwide who will reinvent our future. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best). Parade Magazine (2004) selected Dr. Langer as one of 6 “Heroes whose research may save your life.” Dr. Langer has received 37 honorary doctorates.
Prof. Dan Anderson
Member of the Scientific Advisory Board, Founder of VasoRx
Daniel G. Anderson is a Professor in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and nanotherapeutics, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Anderson’s work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science, and has resulted in the publication of more than 400 papers, patents, and patent applications. These advances have led products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer products space. Dr. Anderson is a founder of Living Proof, Olivo Labs, Crispr Therapeutics (CRSP), Sigilon Therapeutics, Verseau Therapeutics, Orna, and VasoRx
Prof.Dr.Michael Simons
Member of the Scientific Advisory Board, Founder of VasoRx
Dr. Simons is a graduate of Massachusetts Institute of Technology and Yale School of Medicine. He completed his clinical training in internal medicine at the New England Medical Center in Boston and cardiology training at the Beth Israel Hospital in Boston. He completed a postdoctoral fellowships in molecular cardiology at National Heart Lung and Blood Institute in Bethesda and in vascular biology at MIT. In 1993, he joined faculty at Harvard Medical School as an Assistant Professor of Medicine and rose through the ranks to become an Associate Professor of Medicine, Director of the Morse Coronary Care Unit and Director of Angiogenesis Research Center. In 2001, he was recruited to Dartmouth as AG Huber Professor of Medicine and Chief of Cardiology, subsequently becoming Director of Dartmouth Cardiovascular Center.
In 2008, prof Simons accepted the position of the Robert W. Berliner Professor of Medicine, professor of cell biology, and chief of the Section of Cardiovascular Medicine at the Yale CardioVascular Research Center. Dr.Simons has published over 270 research papers and reviews and has been elected to a number of honorary societies.
Prof.dr.Jordan Green
Director of VasoRx
Anthony Ware
Director/ Executive Chair of VasoRx